Physician profile
Shiv Kumar Verma
NPI 1811939747
$8,168.26
in general payments reported to CMS, 2019-2025
34 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $470 · 2021: $1,108 · 2022: $2,253 · 2023: $2,247 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497 · Education: $21.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.88 |
| Education | $21.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,031.46 | 2019-2023 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $926.17 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $828.83 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $789.89 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $651.05 | 2019-2023 | |
| Braintree Laboratories, INC. | $392.06 | 2019-2022 | |
| Gilead Sciences, INC. | $363.73 | 2019-2023 | |
| Ardelyx, INC. | $261.35 | 2022-2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $223.93 | 2021-2023 | Rebyota, Cimzia |
| Organon LLC | $188.93 | 2022-2025 | Renflexis, Nexplanon, Hadlima |
| Redhill Biopharma INC. | $164.36 | 2021-2023 | Talicia |
| Celgene Corporation | $161.68 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $152.77 | 2019-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $148.96 | 2022-2023 | Dupixent |
| Ucb, INC. | $134.17 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $123.05 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $108.33 | 2025 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $102.57 | 2021-2023 | |
| Amgen INC. | $84.35 | 2020-2023 | Avsola, Amjevita |
| Shionogi INC | $45.67 | 2019 | |
| Lucid Diagnostics INC. | $42.89 | 2021 | |
| Daiichi Sankyo INC. | $37.61 | 2019-2023 | Injectafer |
| Fresenius Kabi USA, LLC | $33.84 | 2023 | Idacio |
| Qol Medical, LLC | $30.42 | 2019 | |
| Boston Scientific Corporation | $25.66 | 2023 | Watchman Flx |
| Celltrion USA INC. | $21.17 | 2023 | Yuflyma |
| Oxford Immunotec USA INC | $17.94 | 2022 | |
| Endo Pharmaceuticals INC. | $16.56 | 2019 | |
| Alfasigma USA, INC. | $15.49 | 2022 | |
| Medtronic, INC. | $15.47 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.04 | 2021 | |
| Allergan, INC. | $11.26 | 2019 | |
| Intra-Sana Laboratories | $2.60 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiv Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.